The translocation (8;21) is a chromosome abnormality associated with acute myeloid leukemia (AML). As a consequence of the translocation the AML1 (CBFA2) gene in the 21q22 region is fused to the ETO(CDR,MTG8) gene in the 8q22 region, resulting in one transcriptionally active gene on the 8q− derivative chromosome. In this report we demonstrate the use of a highly specific dual-colour FISH method for the detection of t(8;21) on interphase cells. Genomic probes able to detect the chimeric AML1/ETO gene on the 8q− derivative chromosome were assayed on both normal and leukemic bone marrow and peripheral blood samples. Cut-off values were established by independent analysis of 15 bone marrow specimens negative for the translocation. The cut-off value of positive nuclei was determined to be 2% and the cut-off value for both positive nuclei and nuclei of uncertain classification, 4%. Persistence of cells above these cut-off values was interpreted as persistence of the mutated clone. A total of 36 samples at different disease stages were tested. Interphase cytogenetics detected the translocation at the onset and relapse in the BM or the PB of 14 AML patients with t(8;21). The technique appears to be an alternative tool to both conventional cytogenetics and reverse transcription polymerase chain reaction (RT-PCR) for the monitoring of disease during patients' follow-up. By enabling the analysis of individual cells, interphase FISH is ideal for clonality studies both for clinical and experimental applications.
Introduction
The translocation t (8;21) found in approximately 10% of acute myeloid leukemia (AML) is associated with the FAB-M2 and more seldom with the FAB-M4 subtype. 1 This translocation identifies AML patients with a high complete remission (CR) rate and a probability of longer survival, although the latter feature is still controversial. 2 Relapses are not uncommon, but usually respond to treatment and second, and third and fourth remissions can be obtained. 3 The molecular defect due to the translocation is the fusion of the 5′ region of the AML1/CBFA2 gene, on chromosome 21, to the ETO (CDR, MTG8) gene on chromosome 8. [3] [4] [5] Multiple fusion transcripts, including transcripts sharing the same Correspondence: A Hagemeijer, Center for Human Genetics, University of Leuven, Herestraat 49, 3000 Leuven, Belgium; Fax: +32 16 34 60 63 Received 23 September 1997; accepted 15 October 1997 AML1/ETO junction, were detected in t(8;21)-positive cells. [4] [5] [6] [7] [8] [9] [10] Chimeric AML1 proteins are expressed in cells carrying the translocation and have nuclear localization. 11, 12 Detection of t (8;21) at diagnosis and relapse is performed by conventional cytogenetics and RT-PCR of AML1/ETO transcripts. The latter technique has enabled identification of patients with a cryptic t(8;21) or other t(8;21) variants. [13] [14] [15] [16] [17] [18] Monitoring of patients with t(8;21) AML during the course of the disease includes frequent cytogenetic and molecular tests. Cytogenetic analysis of patients' samples in complete clinical remission (CR) generally shows a normal karyotype, indicating that either the proliferating pool of hematopoietic cells is 'normal' or at least does not derive from the clone carrying the translocation. However, persistence of AML1/ETO transcripts using RT-PCR has been demonstrated in patients in long-term clinical remission following conventional chemotherapy, allogeneic and autologous bone marrow transplantation. [19] [20] [21] [22] [23] [24] This finding has made it difficult to interpret the significance of positive RT-PCR to predict impending relapse in CR patients. 25 More sensitive cytogenetic and RT-PCR methods are being currently developed to offer the possibility of testing for the t(8;21) in suboptimal patients' samples, to achieve a reliable prediction of relapse and to determine the presence of residual leukemic blasts in autologous BM and PB samples prior to transplantation. Quantitative analysis of the AML1/ETO transcript using competitive RT-PCR seems to be a valuable approach for both relapse prediction and estimate of the leukemic contamination in peripheral blood stem cell (PBSC) harvests to be used for autologous transplantation. [26] [27] [28] In this report we describe an interphase cytogenetic test for the t(8;21) based on a dual-colour FISH method 29 and its application on 36 BM and PB samples from 14 t(8;21) AML patients at diagnosis, during follow-up and relapse. We show that this test is highly specific and has a sensitivity greater than conventional cytogenetics.
Materials and methods

Patients
Patients with AML were referred to the cytogenetic laboratory by the Hematology Department of the University Hospital Dijkzigt, the University Children's Hospital Sophia and the Dr Daniel den Hoed Cancer Center (Rotterdam). Fourteen patients (10 males, four females) presented with t(8;21) at diagnosis: for 10 of them, sequential samples were available for study. Relevant clinical data are given in Table 1 . BM from four patients (Nos 7, 9, 10 and 11) obtained at diagnosis were previously studied, using a different methodology. 16 Eleven AML patients with a normal karyotype as well as four BM samples from healthy donors or other non-leukemic patients were used as a control.
Cytogenetics
Cytogenetic analysis of the BM and/or peripheral blood (PB) cells was performed at diagnosis and follow-up, using standard procedures. The chromosomes were identified by R-, Qand/or G-bands and described according to the ISCN. 30 Dual-colour fluorescent in situ hybridization (FISH)
The probes used, a P1 clone (P1164) containing the complete coding sequence of the ETO gene, and a cosmid clone (CO664) encompassing the first five exons of the AML1 gene were previously described (Ref. 29 and unpublished results). Slides prepared for cytogenetic analysis and kept at −20°C were used for interphase FISH. Before hybridization the slides were pre-treated with RNase and pepsine, followed by postfixation and denaturation. Dual-colour FISH was performed as previously reported. 31 Briefly the probes were labelled by nick-translation with biotin-16-dUTP (P1164) or digoxygenin-11-dUTP (CO664) (Boehringer Mannheim, Mannheim, Germany). The probes (5 ng/l, each) were denatured in 70% formamide at 72°C, preannealed with 200× excess Cot-1 DNA for 30 min at 37°C and hybridized overnight. After removal of the excess of probes, hybridization signals were visualized by immunofluorescence using Avidin-FITC and Texas Red conjugated anti-digoxygenin antibodies (Jackson Immuno Research Lab, West Grove, PA, USA). Nuclei and chromosomes were counterstained with DAPI. For each sam- ple, 300-500 nuclei were scored by using a fluorescent microscope equipped with a triple band pass filter for simultaneous excitation of FITC, Texas Red and DAPI.
RT-PCR
Viably stored BM or PB cells were thawed and lysed in 5 m guanidinium isothiocyanate solution. RNA was isolated according to a conventional method. 32 RT-PCR was essentially performed as previously described.
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Results
Interphase FISH on BM samples
The P1 164 and CO664 clones used in this study were previously shown to identify the AML1/ETO fusion gene on the derivative chromosome 8q− both in interphase and metaphase chromosomes, as well as the intact AML1 gene on chromosome 21 and ETO gene on chromosome 8. 29 In this study, the biotin-labelled P1 164 clone was detected by avidin-FITC and gave a green signal on chromosome 8 and 8q−, while the digoxygenin-labelled CO664 clone was detected by a Texas Red conjugated anti-digoxygenin antibody and gave a red signal on chromosome 21 and 8q− (see the metaphase in Figure 1b ). When the same probes were simultaneously hybridized to interphase nuclei, three patterns could be observed. Nuclei with four independent signals, two red and two green (Figure 1c) , were scored as negative (−) for the t(8;21) translocation, nuclei with one red, one green and one red-green (yellow) signal, were scored as positive (+) for the translocation (positive nuclei can be seen in Figure 1a , b and d); nuclei with one red, one green, and one red-green signal close, but not contiguous or overlapping, were of uncertain classification (UC) (Figure 1a, arrow) . 
Determination of cut-off values
Dual-colour FISH was performed on 15 BM samples, 11 from t(8;21)-negative leukemia patients and four from healthy donors or non-leukemia patients. Approximately 500 nuclei were analyzed for each sample. Results are shown in Table 2 . In each case most of the nuclei (98.5-99.5%) scored negative (−), and a minority scored positive (+) or of uncertain classification (UC). The (+) and (UC) nuclei, probably due to random juxtaposition of the probes in the chromatin, represent all false positives. We could see fewer false positives in PHAstimulated PB cultures vs BM (data not shown). The cut-off value for (+) nuclei alone was 2% and the cut-off value for both (+) and (UC) nuclei was 4% (see Table 2 ). These values, calculated as either the mean of (+) nuclei +3 standard deviation (s.d.) values, or the mean of (+) and (UC) nuclei +3 s.d. represent the technical limits for the detection of residual disease, using the P1 164 and CO664 probes.
Interphase FISH on t(8;21) AML samples BM or PB (36 samples) of 14 patients with AML, cytogenetically positive for the t(8;21) were analyzed at different disease stages with interphase FISH. In most cases both the karyotype and the presence of AML1/ETO transcripts were determined on the same samples. A first (I) PCR was sometimes followed by a second (II) round of PCR. The results of the overall analysis are summarized in Table 3 . FISH on interphase cells was suitable to detect the translocation at the diagnosis/relapse stages in all 14 patients. At these stages 98 to 74% of the nuclei scored positive in the interphase FISH.
Follow-up BM or PB samples and PBSC collections were obtained for 10 patients within 3 and 36 months after diagnosis and the beginning of treatment. In these samples interphase FISH could detect the translocation in patients 1, 5, 8, 9 and 13 during follow-up whereas the conventional cytogenetics did not (Table 3 ). According to the 4% threshold established in the control experiments (Table 2) , minimal residual disease could be concluded on the basis of interphase FISH alone, in patients 1, 5, 8 and 9 and 13, where less than 96% nuclei scored negative (Table 3 ). Interphase cytogenetics data were supported by detection of AML1/ETO transcripts in PB samples in patients 1, 5 and 9 using RT-PCR. From the close analysis of interphase FISH data during the follow-up of a few patients (1, 5, 7, 8, 9) , we can conclude that it is not possible to predict relapse on the basis of these data alone or in combination with RT-PCR results.
Discussion
We report the development of a dual-color interphase FISH test, for the assessment of the presence of t(8;21) in patients' samples, including BM, PB and PBSC. The genomic probes selected for this application could specifically demonstrate the critical recombinant chromosome 8q− of t(8;21) and its variants. Numerical changes in normal chromosomes 8 and 21 were seen as gain or loss of a single color signal. We 16 and others 2 previously analyzed the t(8;21) by using AML1-specific cosmid and YAC probes by one and two-color FISH, respectively. However, these probes were not specific for the t(8;21) and could also detect deletions or translocations involving AML1. The labelling and detection protocol that we used allows the easy and rapid identification of FISH signals with a conventional fluorescence microscope equipped with adequate double or triple band pass filters, without the need of a computer assisted cooled camera or any other system for signal amplification.
The BM samples that we used as controls enabled us to establish that the cut-off value for false positive is 2%. The cut-off value for both positive and nuclei of uncertain classification was calculated to be 4%. According to this limit, any sample with a percentage of positive nuclei below 4% has to be considered a remission. Persistence of positive nuclei above this cut-off value has to be considered as persistence of the mutated clone.
According to these criteria, we tested the samples of 14 patients at different stages of t(8;21) leukemia. We can conclude that interphase FISH is a valid and relatively fast method to detect the translocation in patients' samples at diagnosis, follow-up and relapse. Interphase cytogenetics could detect the translocation when conventional cytogenetics could not, because 15 to 20 times more cells can be easily scored in a given sample. Moreover, by interphase FISH both proliferating and not proliferating cells can be analyzed. Based on interphase FISH data alone, assessment of the translocation, and consequent confirmation of diagnosis and relapse, was possible in all 14 cases including two cases presenting with complex translocations. Assessment of the translocation was also possible during follow-up. Taking into consideration the interphase FISH threshold (Table 2) , minimal residual disease could be established in six instances during the follow-up of five patients (1, 5, 8, 9, 13) . At close scrutiny, interphase FISH results were not always consistent with both clinical data and evolution of the disease period as can be seen in Tables 1 and  3: patient 8 was not yet in CR, patient 1 relapsed 5 months after a slight positive score, the relapses of patients 7 and 9 were not predicted, while twice in patients 5 and 13, a slight positive score was followed by a negative score and this corresponded to continuing CR. Thus, prediction of relapse based on interphase FISH alone is not yet possible. The sensitivity of 10 −2 is such that positive detection of residual leukemia should require closer monitoring and therapeutic attention. On the other hand, failure to detect residual cells does not exclude the occurrence of relapse in the months following the test.
Presently, also positive RT-PCR per se is not a reliable predicting factor of impending relapse. In addition to quantitative PCR, [26] [27] [28] improved FISH methods that can achieve a sensitivity of 10 −3 /10 −4 need to be developed to make possible the prediction of relapse in t(8;21) AML. [33] [34] [35] In conclusion, the data obtained in this preliminary study indicate that dual-color interphase FISH is a highly specific and quantitative test to assess the presence of t(8;21) in patients' samples at different disease stages. The test can be reliably used for routine diagnostic screening and whenever the patient's material is not sufficient or suitable for cytogenetic/RT-PCR analysis. Moreover, interphase FISH is more efficient than conventional cytogenetics in detecting the translocation during follow-up.
A major advantage of interphase karyotyping is the possibility of performing simultaneous analysis of cell morphology of individual haematopoietic cells. So far, this approach applied to six t(8;21) AML samples indicated that the translocation is restricted to the myeloid lineage. 36 
